Menu Search
Equities

Vanda Pharmaceuticals Inc

VM4:DEU

Vanda Pharmaceuticals Inc

Actions
  • Price (EUR)4.78
  • Today's Change-0.14 / -2.85%
  • Shares traded0.00
  • 1 Year change+47.53%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Vanda Pharmaceuticals Inc's revenues fell -24.27% from 254.38m to 192.64m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 6.28m to 2.51m, a -60.02% decrease.
Gross margin93.62%
Net profit margin-8.59%
Operating margin-19.64%
Return on assets-2.55%
Return on equity-3.02%
Return on investment-2.95%
More ▼

Cash flow in USDView more

In 2023, Vanda Pharmaceuticals Inc did not generate a significant amount of cash. However, the company earned 12.80m from its operations for a Cash Flow Margin of 6.65%. In addition the company used 12.06m on investing activities while cash flow from financing was even.
Cash flow per share-0.1564
Price/Cash flow per share--
Book value per share9.28
Tangible book value per share7.30
More ▼

Balance sheet in USDView more

Vanda Pharmaceuticals Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio4.85
Quick ratio4.84
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)-37.98
EPS (TTM) vs
TTM 1 year ago		-239.61
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.